262 related articles for article (PubMed ID: 26951625)
1. Ocular toxicities of MEK inhibitors and other targeted therapies.
Stjepanovic N; Velazquez-Martin JP; Bedard PL
Ann Oncol; 2016 Jun; 27(6):998-1005. PubMed ID: 26951625
[TBL] [Abstract][Full Text] [Related]
2. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
3. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.
Duncan KE; Chang LY; Patronas M
Eye (Lond); 2015 Aug; 29(8):1003-12. PubMed ID: 26043707
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
6. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.
Méndez-Martínez S; Calvo P; Ruiz-Moreno O; Pardiñas Barón N; Leciñena Bueno J; Gil Ruiz MDR; Pablo L
Retina; 2019 Aug; 39(8):1435-1450. PubMed ID: 30681641
[TBL] [Abstract][Full Text] [Related]
7. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.
Maubon L; Hirji N; Petrarca R; Ursell P
Eye (Lond); 2016 Feb; 30(2):330. PubMed ID: 26584794
[No Abstract] [Full Text] [Related]
8. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
9. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH
Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072
[TBL] [Abstract][Full Text] [Related]
10. Emerging MEK inhibitors.
McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
Expert Opin Emerg Drugs; 2010 Jun; 15(2):203-23. PubMed ID: 20151845
[TBL] [Abstract][Full Text] [Related]
11. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
12. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Niro A; Strippoli S; Alessio G; Sborgia L; Recchimurzo N; Guida M
Am J Ophthalmol; 2015 Nov; 160(5):959-967.e1. PubMed ID: 26231307
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
15. Novel targets in solid tumors: MEK inhibitors.
Messersmith WA; Hidalgo M; Carducci M; Eckhardt SG
Clin Adv Hematol Oncol; 2006 Nov; 4(11):831-6. PubMed ID: 17143253
[TBL] [Abstract][Full Text] [Related]
16. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
17. MEK in cancer and cancer therapy.
Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
[TBL] [Abstract][Full Text] [Related]
18. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation.
Jeng-Miller KW; Miller MA; Heier JS
Oncologist; 2024 May; 29(5):e616-e621. PubMed ID: 38527005
[TBL] [Abstract][Full Text] [Related]
19. Ocular and orbital side effects of ALK inhibitors: a review article.
Chelala E; Hoyek S; Arej N; Kattan J; Kourie HR; Baakliny J; Antoun J
Future Oncol; 2019 Jun; 15(16):1939-1945. PubMed ID: 31140869
[TBL] [Abstract][Full Text] [Related]
20. Retinal toxicities of systemic anticancer drugs.
Arora S; Surakiatchanukul T; Arora T; Errera MH; Agrawal H; Lupidi M; Chhablani J
Surv Ophthalmol; 2022; 67(1):97-148. PubMed ID: 34048859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
